Cellectis SA (CLLS) has launched an replace.
Cellectis SA’s UCART22, a gene-edited CAR T-cell product candidate, has acquired Orphan Drug and Uncommon Pediatric Illness...
CancerNetwork® spoke with Nazli Dizman, MD, a hematology/oncology fellow at The College of Texas MD Anderson Most cancers Middle, about future instructions associated...
